Journal of General Internal Medicine

, Volume 18, Issue 11, pp 937–947 | Cite as

Meta-analysis of vascular and neoplastic events associated with tamoxifen

  • R. Scott Braithwaite
  • Rowan T. Chlebowski
  • Joseph Lau
  • Suzanne George
  • Rachel Hess
  • Nananda F. Col


OBJECTIVE: Tamoxifen reduces the risk of developing breast cancer but also affects the risks of certain vascular and neoplastic events. Our purpose was to estimate the effects of tamoxifen on potentially life-threatening vascular and neoplastic outcomes.

DESIGN: Random effects meta-analysis of published randomized controlled trials.

PATIENTS: Participants in all trials in which a treatment arm that included tamoxifen was compared to a similar control arm. Breast cancer risk reduction and treatment trials were included.

INTERVENTIONS: Tamoxifen at variable dose and duration.

MEASUREMENTS AND MAIN RESULTS: Thirty-two trials (52,929 patients) reported one or more outcomes of interest. Tamoxifen was associated with significantly increased risks of endometrial cancer (relative risk [RR] 2.70; 95% CI, 1.94 to 3.75), gastrointestinal cancers (RR 1.31; 95% CI, 1.01 to 1.69), strokes (RR 1.49; 95% CI, 1.16 to 1.90), and pulmonary emboli (RR 1.88; 95% CI, 1.77 to 3.01). Tamoxifen had no effect on secondary malignancies other than endometrial and gastrointestinal cancers (RR 0.96; 95% CI, 0.81 to 1.13). In contrast, tamoxifen significantly decreased myocardial infarction deaths (RR 0.62; 95% CI, 0.41 to 0.93) and was associated with a statistically insignificant decrease in myocardial infarction incidence (RR 0.90; 95% CI, 0.66 to 1.23). Postmenopausal women had greater risk increases for neoplastic outcomes.

CONCLUSIONS: This meta-analysis of randomized trials found tamoxifen use to be significantly associated with several neoplastic and vascular outcomes. Consideration of tamoxifen use requires balance of potential benefits and risks.

Key words

tamoxifen adverse events selective estrogen receptor modulators chemoprevention 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339:1609–18.PubMedCrossRefGoogle Scholar
  2. 2.
    Chlebowski RT. Reducing the risk of breast cancer. N Engl J Med. 1998;343:191–8.CrossRefGoogle Scholar
  3. 3.
    Chlebowski RT, Col NF, Winer EP, et al. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase reduction. J Clin Oncol. 2002;20:3328–43.PubMedCrossRefGoogle Scholar
  4. 4.
    Anonymous. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 1998;351:1451–67.Google Scholar
  5. 5.
    Hasselblad V, McCrory DC. Meta-analytic tools for medical decision making: a practical guide. Med Decis Making. 1995;15:81–96.PubMedCrossRefGoogle Scholar
  6. 6.
    Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Int Med. 1997;127:820–6.PubMedGoogle Scholar
  7. 7.
    Berlin JA, Laird NM, Sacks HS, et al. A comparison of statistical methods for combining event rates from clinical trials. Stat Med. 1989;8:141–51.PubMedCrossRefGoogle Scholar
  8. 8.
    Fisher B, Constantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371–88.PubMedCrossRefGoogle Scholar
  9. 9.
    Powles T, Eles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet. 1998;252:98–101.Google Scholar
  10. 10.
    Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomized women. Lancet. 1998;352:93–7.PubMedGoogle Scholar
  11. 11.
    Veronesi U, Maisonneuve P, Sacchini V, et al. Tamoxifen for breast cancer among hysterectomized women. Lancet. 2002;359:1122–4.PubMedCrossRefGoogle Scholar
  12. 12.
    IBIS Investigators. First results from the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trial. Lancet. 2002;360:817–24.CrossRefGoogle Scholar
  13. 13.
    Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996;88:1529–42.PubMedCrossRefGoogle Scholar
  14. 14.
    Fisher B, Constantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994;86:527–37.PubMedCrossRefGoogle Scholar
  15. 15.
    Constantino JP, Kuller LH, Ives DG, et al. Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst. 1997;89:776–82.CrossRefGoogle Scholar
  16. 16.
    Barner M, Bacchi M, Goldhirsch A, et al. First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase 3 multicenter study comparing systemic treatment with observation after excision and radiation. J Clin Oncol. 1994;12:2071–7.Google Scholar
  17. 17.
    Ribeiro G, Swindell R. The Christie Hospital Adjuvant Tamoxifen Trial. J Natl Cancer Inst Monogr. 1992;11:121–5.PubMedGoogle Scholar
  18. 18.
    Rutqvist LE, Johansson H. Signomkalo, et al. Adjuvant tamoxifen therapy for early stage breast cancer and secondary primary malignancies. J Natl Cancer Inst. 1995;87:645–51.PubMedCrossRefGoogle Scholar
  19. 19.
    Ryden S, Ferno M, Moller T, et al. Long term effects of adjuvant tamoxifen and/or radiotherapy. Acta Oncol. 1992;31:271–4.PubMedGoogle Scholar
  20. 20.
    Andersson M, Storm HH, Mouridsen HT. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst. 1991;83:1013–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Dalberg K, Johansson H, Johansson U. A randomized trial of long term adjuvant tamoxifen plus postoperative radiation therapy versus radiation therapy alone for patients with early stage breast carcinoma treated with breast-conserving surgery. Cancer. 1998;82:2204–11.PubMedCrossRefGoogle Scholar
  22. 22.
    Rutqvist LE, Mattson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst. 1993;85:1398–406.PubMedCrossRefGoogle Scholar
  23. 23.
    Fornander T, Rutqvist LE, Cedermark B, et al. Adjuvant tamoxifen in early-stage breast cancer: effects on intercurrent morbidity and mortality. J Clin Oncol. 1991;9:1740–8.PubMedGoogle Scholar
  24. 24.
    Cummings FJ, Gray R, Tormey DC, et al. Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long term follow-up and causes of death. J Clin Oncol. 1993;11:29–35.PubMedGoogle Scholar
  25. 25.
    Alwyn van Zyl J, Muller AG. Tumor excision plus continuous tamoxifen compared with modified radical mastectomy in patients over 70 years of age with operable breast cancer. J Surg Oncol. 1995;59:151–4.CrossRefGoogle Scholar
  26. 26.
    Ingle JN, Everson LK, Wieland HS, et al. Randomized trial of observation versus adjuvant therapy with cyclophosphamide, fluorouracil, prednisone with or without tamoxifen following mastectomy in postmenopausal women with node-positive breast cancer. J Clin Oncol. 1988;6:1388–96.PubMedGoogle Scholar
  27. 27.
    Ingle JN, Everson LK, Weiland HS, et al. Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with nodepositive breast cancer. Cancer. 1989;63:1257–64.PubMedCrossRefGoogle Scholar
  28. 28.
    Rivkin SE, Green S, Metch B, et al. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group Study. J Clin Oncol. 1994;12:2078–85.PubMedGoogle Scholar
  29. 29.
    Love RR, Wiebe DA, Feyzi JM, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst. 1994;86:1534–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Fisher B, Digham J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial. Lancet. 1999;353:1993–2000.PubMedCrossRefGoogle Scholar
  31. 31.
    Boccardo F, Rubagotti A, Amoroso D, et al. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-hormone Therapy Cooperative Group) trial. Eur J Cancer. 1992;28:673–80.PubMedCrossRefGoogle Scholar
  32. 32.
    Gundersen S, Hannisdal E, Soreide JA, et al. Adjuvant tamoxifen for pre- and postmenopausal women with estrogen receptor positive, node positive breast cancer: a randomized study. Breast Cancer Res Treat. 1995;36:49–53.PubMedCrossRefGoogle Scholar
  33. 33.
    Stewart HJ. The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. J Natl Cancer Inst Monogr. 1992;11:117–20.PubMedGoogle Scholar
  34. 34.
    McDonald CC, Alexander FE, Whyte BW, et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial. BMJ. 1995;311:977–80.PubMedGoogle Scholar
  35. 35.
    McDonald CC, Stewart HJ. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. BMJ. 1991;303:435–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Stewart HJ, Prescott RJ, Forrest PM. Scottish Adjuvant Tamoxifen Trial: a randomized study updated to 15 years. J Natl Cancer Inst. 2001;93:456–62.PubMedCrossRefGoogle Scholar
  37. 37.
    Taylor SG, Kalish LA, Olson JE, et al. Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, nodepositive breast cancer patients: three year results of an Eastern Cooperative Oncology Group Study. J Clin Oncol. 1985;3:144–54.PubMedGoogle Scholar
  38. 38.
    Tormey DC, Gray R, Taylor SG, et al. Postoperative chemotherapy and chemohormonal therapy in women with node-positive breast cancer. J Natl Cancer Inst Monogr. 1986;1:75–80.Google Scholar
  39. 39.
    Cocconi G, De Lisi V, Boni C, et al. Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. Cancer. 1983;51:581–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Cocconi G, Di Blasio B, Bisagni G, et al. Neoadjuvant chemotherapy or chemotherapy and endocrine therapy in locally advanced breast carcinoma. Am J Clin Oncol. 1990;13:226–32.PubMedCrossRefGoogle Scholar
  41. 41.
    Robertson JR, Ellis IO, Elston CW, et al. Mastectomy of tamoxifen as initial therapy for operable breast cancer in elderly patients: 5 year follow-up. Eur J Cancer. 1992;28A:908–10.PubMedCrossRefGoogle Scholar
  42. 42.
    Andersson M, Kamby C, Jensen MB, et al. Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer Co-operative Group DBCG 82B Trial. Eur J Cancer. 1999;35:1659–66.PubMedCrossRefGoogle Scholar
  43. 43.
    The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group. Anastrazol alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet. 2002;359:2131–9.CrossRefGoogle Scholar
  44. 44.
    Fisher B, Anderson S, Tan-Chiu E, et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B23. J Clin Onc. 2001;19:931–42.Google Scholar
  45. 45.
    Klijn JG, Beex LV, Mauriac L, et al. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst. 2000;92:903–11.PubMedCrossRefGoogle Scholar
  46. 46.
    Rusthoven JJ, Quirt IC, Iscoe NA, et al. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. J Clin Oncol. 1996;14:2083–90.PubMedGoogle Scholar
  47. 47.
    Agarwala SS, Ferri W, Gooding W, et al. A phase 3 randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer. 1999;85:1979–84.PubMedGoogle Scholar
  48. 48.
    Cocconi G, Bella M, Calabresi F, et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med. 1992;327:516–23.PubMedCrossRefGoogle Scholar
  49. 49.
    Kinsinger LS, Harris R, Woolf SH, et al. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:59–67.PubMedGoogle Scholar
  50. 50.
    Newcomb P, Solomon C, White E. Tamoxifen and risk of large bowel cancer in women with breast cancer. Breast Cancer Res Treat. 1999;53:271–7.PubMedCrossRefGoogle Scholar
  51. 51.
    Matsuyama Y, Tominaga T, Nomura Y, et al. Second cancers after adjuvant tamoxifen therapy for breast cancer in Japan. Ann Oncol. 2000;11:1337–43.CrossRefGoogle Scholar
  52. 52.
    Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA. 2002;288:321–33.CrossRefGoogle Scholar
  53. 53.
    Williams KJ, Wagner JD, Zhang L, et al. Tamoxifen inhibits arterial accumulation of LDL degradation products and progression of coronary artery atherosclerosis in monkeys. Arterioscler Thromb Vasc Biol. 1997;17:403–8.PubMedGoogle Scholar
  54. 54.
    Williams KJ, Honore EK, Adams MR. Contrasting effects of conjugated estrogens and tamoxifen on dilator responses of atherosclerotic epicardial coronary arteries nonhuman primates. Circulation. 1997;96:1970–75.PubMedGoogle Scholar
  55. 55.
    Clarke SC, Schofield PM, Grace AA, et al. Tamoxifen effects on endothelial function and cardiovascular risk factors in men with advanced atherosclerosis. Circulation. 2001;103:1497–502.PubMedGoogle Scholar
  56. 56.
    Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med. 1991;115:860–4.PubMedGoogle Scholar
  57. 57.
    Cushman M, Tracy JP, Song RP, et al. Tamoxifen and cardiac risk factors in healthy women: suggestion of an anti-inflammatory effect. Arterioscler Thromb Vasc Biol. 2001;21:255–61.PubMedGoogle Scholar
  58. 58.
    Figtree GA, Webb CM, Collins P. Tamoxifen acutely relaxes coronary arteries by an endothelium-, nitric oxide-, and estrogen receptor-dependent mechanism. J Pharmacol Exp Ther. 2000;295:519–23.PubMedGoogle Scholar
  59. 59.
    Love RR, Surawicz TS, Williams EC. Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy. Arch Intern Med. 1992;152:317–20.PubMedCrossRefGoogle Scholar
  60. 60.
    Reis SE, Constantino JP, Wickerham DL, et al. Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. J Natl Cancer Inst. 2001;93:16–21.PubMedCrossRefGoogle Scholar
  61. 61.
    Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women. JAMA. 2002;287:847–57.PubMedCrossRefGoogle Scholar
  62. 62.
    Kuzick J. Update on new studies in Europe. Eur J Cancer. 2002;38:S20.Google Scholar

Copyright information

© Society of General Internal Medicine 2003

Authors and Affiliations

  • R. Scott Braithwaite
    • 5
  • Rowan T. Chlebowski
    • 1
  • Joseph Lau
    • 2
  • Suzanne George
    • 3
  • Rachel Hess
    • 5
  • Nananda F. Col
    • 4
  1. 1.Harbor-UCLA Research and Education InstituteTorrance
  2. 2.Tufts-New England Medical CenterBoston
  3. 3.Dana Farber Cancer CenterHarvard Medical SchoolBoston
  4. 4.the Decision Systems Group and Division of General Medicine, Department of Medicine, Brigham and Women’s HospitalHarvard Medical SchoolBoston
  5. 5.Section of Clinical Systems Modeling, Division of General Internal Medicine, Department of MedicineUniversity of PittsburghPittsburgh

Personalised recommendations